Background Clostridium difficile infection (CDI) is the leading cause of infectious nosocomial
diarrhoea but the economic costs of CDI on healthcare systems in the US remain uncertain …

Infectious complications are major causes of morbidity and mortality after liver
transplantation, despite recent advances in the transplant field. Bacteria, fungi, viruses and …

Objectives: WithClostridium difficileinfection (CDI) on the rise, knowledge of the current
economic burden of CDI can inform decisions on interventions related to CDI. We …

Clostridium difficile infection (CDI) is an emerging problem worldwide associated with
significant morbidity, mortality, recurrence rates and healthcare costs. Immunosuppressed …

Abstract Background and Aim Clostridioides difficile infection (CDI) is the leading cause of
hospital acquired‐infectious diarrhea in the USA. In this study, we assess the prevalence …

BACKGROUNDThe incidence of Clostridium difficile infection (CDI) has increased among
hospitalized patients and is a common complication of leukemia. We investigated the risks …

Objective: To describe 12-month outcomes for beneficiaries in the 100% Medicare Fee-for-
Service (FFS) population with primary and recurrent Clostridioides difficile infection (CDI) …

Clostridium difficile infection (CDI) occurs in 3–7% of liver transplant recipients (LTR).
However, few data exist on the recent epidemiology, predictors and outcomes of CDI in LTR …

Background Patients with cirrhosis are at high risk of Clostridium difficile infection (CDI).
Rifaximin is commonly used in cirrhotic patients as prophylaxis for hepatic encephalopathy …

Over the past two decades, there has been a dramatic worldwide increase in both the
incidence and severity of Clostridium difficile infection (CDI). Paralleling the increased …